Compare · ICU vs RMD
ICU vs RMD
Side-by-side comparison of SeaStar Medical Holding Corporation (ICU) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICU and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $29.41B, about 1743.7x ICU ($16.9M).
- Over the past year, ICU is down 37.1% and RMD is down 22.3% - RMD leads by 14.8 points.
- ICU has been more active in the news (11 items in the past 4 weeks vs 7 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 0 for ICU).
- Company
- SeaStar Medical Holding Corporation
- ResMed Inc.
- Price
- $4.15-2.81%
- $199.06-1.82%
- Market cap
- $16.9M
- $29.41B
- 1M return
- +36.96%
- +2.64%
- 1Y return
- -37.14%
- -22.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 7
- Recent ratings
- 0
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ICU
- SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
- Chief Executive Officer Schlorff Eric was granted 10,288 shares, increasing direct ownership by 26% to 50,140 units (SEC Form 4)
- Chief Medical Officer Chung Kevin was granted 7,202 shares, increasing direct ownership by 35% to 28,021 units (SEC Form 4)
- Director Vincent Bernadette N was granted 4,000 shares, increasing direct ownership by 95% to 8,200 units (SEC Form 4)
- Director Neuman John was granted 4,000 shares, increasing direct ownership by 33% to 16,200 units (SEC Form 4)
- Director Van Heel Kenneth was granted 4,000 shares, increasing direct ownership by 50% to 11,940 units (SEC Form 4)
- Director Baird Jennifer A was granted 4,000 shares, increasing direct ownership by 60% to 10,620 units (SEC Form 4)
- SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update
- SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)